Increase of size of an armpit lymph node and soreness; Increase of size of an armpit lymph node and soreness; Pain on the injection site; Red patchy rash on the injection site going to armpit; This spontaneous case was reported by a consumer and describes the occurrence of LYMPH NODE PAIN (Increase of size of an armpit lymph node and soreness), LYMPHADENOPATHY (Increase of size of an armpit lymph node and soreness), VACCINATION SITE PAIN (Pain on the injection site) and VACCINATION SITE ERYTHEMA (Red patchy rash on the injection site going to armpit) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.). Concomitant products included LEVOTHYROXINE SODIUM (LEVOTIROXIN) for an unknown indication.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jan-2021, the patient experienced LYMPH NODE PAIN (Increase of size of an armpit lymph node and soreness), LYMPHADENOPATHY (Increase of size of an armpit lymph node and soreness), VACCINATION SITE PAIN (Pain on the injection site) and VACCINATION SITE ERYTHEMA (Red patchy rash on the injection site going to armpit). At the time of the report, LYMPH NODE PAIN (Increase of size of an armpit lymph node and soreness), LYMPHADENOPATHY (Increase of size of an armpit lymph node and soreness), VACCINATION SITE PAIN (Pain on the injection site) and VACCINATION SITE ERYTHEMA (Red patchy rash on the injection site going to armpit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the events included cefalexin 500mg 3 times a day.  This case concerns a 52-year-old female who had a NS unexpected event of lymph node pain, and NS expected events of lymphadenopathy, vaccination site pain, vaccination site erythema. This case concerns a 52-year-old female who had a NS unexpected event of lymph node pain, and NS expected events of lymphadenopathy, vaccination site pain, vaccination site erythema. Event onset occurred 11 days after the first dose of mRNA-1273. Treatment for the events included cefalexin 500mg 3 times a day. Outcomes not reported. Based on current available information and temporal association between use of the product and the start date of the event, a causal relationship cannot be excluded.  Event onset occurred 11 days after the first dose of mRNA-1273. Treatment for the events included cefalexin 500mg 3 times a day. Outcomes not reported. Based on current available information and temporal association between use of the product and the start date of the event, a causal relationship cannot be excluded.; Reporter's Comments: This case concerns a 52-year-old female who had a NS unexpected event of lymph node pain, and NS expected events of lymphadenopathy, vaccination site pain, vaccination site erythema. This case concerns a 52-year-old female who had a NS unexpected event of lymph node pain, and NS expected events of lymphadenopathy, vaccination site pain, vaccination site erythema. Event onset occurred 11 days after the first dose of mRNA-1273. Treatment for the events included cefalexin 500mg 3 times a day. Outcomes not reported. Based on current available information and temporal association between use of the product and the start date of the event, a causal relationship cannot be excluded.  Event onset occurred 11 days after the first dose of mRNA-1273. Treatment for the events included cefalexin 500mg 3 times a day. Outcomes not reported. Based on current available information and temporal association between use of the product and the start date of the event, a causal relationship cannot be excluded.